UK Edition
AdvertiseSubmit Company
Pharma JournalEvidence-Based Pharmaceutical Intelligence
FERTILITY & IVF

Hamilton Thorne

H

Hamilton Thorne

Fertility & IVFBeverly, United States
Visit Website

About Hamilton Thorne

Hamilton Thorne has built its reputation as the leading supplier of precision instruments and consumables for the assisted reproductive technology (ART) sector, serving IVF clinics, fertility research laboratories, and pharmaceutical and biotechnology companies worldwide.

Founded in 1991 and headquartered in Beverly, Massachusetts, the company develops and markets a portfolio of laser systems, imaging systems, and embryo assessment software designed to improve clinical outcomes in human and animal reproductive medicine. Its LYKOS laser platform and OOSIGHT imaging systems are among the most widely recognised tools in clinical IVF environments globally.

Hamilton Thorne is publicly traded on the TSX Venture Exchange under the ticker HLT, giving it a capital markets profile uncommon among specialist ART equipment suppliers. The company has grown significantly through acquisition, adding complementary businesses in consumables, cryopreservation, and laboratory services to build a more complete offering for fertility clinics and research organisations.

Its customer base spans fertility clinics, academic research centres, and pharmaceutical companies conducting reproductive toxicology studies. The company also serves the animal breeding and veterinary reproduction market, supplying sperm analysis instruments and related products used in equine, bovine, and companion animal fertility work.

Further information is available at hamiltonthorne.com.

Similar Companies

More in Fertility & IVF

I

IVIRMA Global

The world's largest network of assisted reproduction clinics, IVIRMA Global was formed in 2017 when two established fertility leaders, IVI (founded 1990 in Valencia, Spain) and RMA (founded 1999 in the United States), merged to create a single, vertically integrated group spanning Europe, North America and Latin America. Headquartered in Valencia, the group has since grown to more than 200 clinical offices across 15 countries, treating patients who travel from more than 180 countries each year. Clinical Services Across the Reproductive Medicine Spectrum IVIRMA Global's clinical portfolio covers the full range of reproductive medicine, including in vitro fertilisation (IVF), intrauterine insemination, egg freezing and fertility preservation, third-party reproduction (donor eggs, donor sperm and gestational carriers), reproductive surgery (laparoscopy, hysteroscopy and myomectomy), and pre-implantation genetic testing. Services are structured to serve heterosexual couples, same-sex couples and single individuals. The group performs more than 200,000 assisted reproduction treatments annually, with approximately 100 babies born every day as a direct result of its programmes. Research, Science and the IVIRMA Innovation Network Scientific output is central to the group's identity. IVIRMA Innovation, its dedicated research arm, operates a network of fertility research centres and supports clinical trials, making the group one of the most cited organisations in peer-reviewed reproductive medicine literature. The group employs more than 6,000 people globally, including over 450 physicians and embryologists and more than 500 scientists and researchers. Patient-facing technology includes the Artemis Patient Portal, which centralises treatment management and communication. Financial access programmes, including a CareShare IVF refund programme, reflect a broader commitment to widening access to treatment. In 2025, IVIRMA Global continued its international expansion, acquiring ART Fertility Clinics in the United Arab Emirates and Saudi Arabia, extending its footprint into the Gulf region. Executive Chairman Dr Antonio Pellicer, one of the original founders of IVI, remains the public face of the group's scientific leadership. Further information is available at ivirma.com.

View profile
V

Vitrolife

Pioneering the science of human fertility, Vitrolife is a Swedish medtech company whose products are used in IVF clinics across more than 110 countries. Founded in 1994 and headquartered in Gothenburg, Sweden, the group has grown into one of the most recognised names in assisted reproductive technology, supplying the consumables, media and equipment that laboratories depend on throughout the IVF process. The company's portfolio centres on IVF culture media, time-lapse incubation systems, and associated laboratory consumables. Its time-lapse technology, which allows embryologists to monitor embryo development continuously without disturbing the culture environment, has become widely adopted in fertility clinics worldwide. Vitrolife is listed on Nasdaq Stockholm, reflecting its standing as a significant publicly traded entity in the European medtech sector. A major expansion came through the acquisition of Igenomix in 2021, broadening Vitrolife's capabilities into reproductive genetics, including preimplantation genetic testing services used to assess embryo chromosomal status before transfer. This move extended the group's reach well beyond physical laboratory products and into genomic diagnostics for fertility treatment. Vitrolife operates its own manufacturing and research facilities, and its scientific teams publish regularly in peer-reviewed reproductive medicine literature. The company serves fertility specialists, reproductive biologists, and IVF laboratory directors, positioning itself as a full-cycle partner from fertilisation through embryo selection and transfer. Further information is available at vitrolife.com.

View profile
F

Ferring Pharmaceuticals

Ferring Pharmaceuticals is the company behind desmopressin, the world's most widely prescribed treatment for bedwetting in children, and has built its entire identity around reproductive medicine and maternal health, areas where most large pharmaceutical companies remain peripheral players. Founded in 1950 by Frederik Pauling in Malmö, Sweden, Ferring has grown into a privately held, research-driven biopharmaceutical company operating in more than 100 countries across six continents. Reproductive Medicine & Women's Health Ferring holds a leading global position in reproductive medicine, supplying the gonadotropins and other hormone therapies that fertility clinics rely on at scale. Its Fertility portfolio includes products used in controlled ovarian stimulation protocols for in vitro fertilisation, making Ferring one of the few pharmaceutical companies for which assisted reproduction constitutes a primary, not peripheral, business line. The company has also invested heavily in maternal health, developing treatments to reduce the risk of preterm birth. Urology & Gastroenterology Beyond reproductive health, Ferring carries significant franchises in urology and gastroenterology. Its peptide-derived therapies span nocturia, enuresis and prostate cancer, reflecting a longstanding expertise in peptide science that dates to the company's earliest research. In gastroenterology, Ferring has pursued microbiome-based therapeutics, and in 2023 received FDA approval for Rebyota, the first faecal microbiota product approved for preventing recurrent Clostridioides difficile infection, a milestone that marks Ferring's entry into the emerging field of microbiome medicine. Headquartered in Saint-Prex, Switzerland, with major research operations in Copenhagen and commercial presence across North America, Europe and Asia-Pacific, Ferring remains family-owned and privately held, which affords it a longer investment horizon than many listed peers. The company consistently channels a substantial proportion of revenues back into research and development, particularly in peptide synthesis, reproductive endocrinology and next-generation microbiome therapies. Its scale, independence and therapeutic focus make it a distinctive reference point within the global specialty pharmaceuticals landscape. Further information is available at ferring.com.

View profile
AdvertisementTeksyte LTD

List Your Company

Showcase your company to thousands of pharma professionals.

Submit Listing

Advertise With Us

Reach decision-makers in the pharmaceutical industry.

Learn More

We use cookies and analytics to understand how the site is used and to keep the service free. Choose Accept All to allow this, or Essential Only to use just the cookies we need to keep the site working. You can change your choice any time in our Cookie Policy